Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Five diagnosed prevalent cases will grow to over 714,000. Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) across the seven major markets (7MM) are expected to increase from 200, ...

A lymph node biopsy is the main method of diagnosing both non-Hodgkin’s and Hodgkin’s lymphoma, including diffuse large B-cell lymphoma, which is the most common form of non-Hodgkin’s lymphoma.

in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R 2 alone - Phase 2 portion of trial in patients with ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Additional requirements for inclusion were: performance score (PS) < 4 (WHO), no severe comorbidity, no concomitant malignancy (nonmelanoma skin tumors ... or a non-PTCL histology (n = 8; [Hodgkin's ...

Epcoritimab is a treatment for diffuse large B-cell lymphoma, a form of Non-Hodgkin lymphoma affecting 2000 Australians annually and characterised by its aggressive growth. Set to be subsidised by ...

in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting taking place May 13-17, 2025, in New Orleans ...